From: Physiological and pathological aspects of Aβ in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators
Drug
Inhibition (% of control)
M30 (20 μM)
7.1 ± 1.07 *
M30 (100 μM)
33.7 ± 8.3†
HLA20 (20 μM)
16.2 ± 2.4†
HLA20 (100 μM)
27.3 ± 2.9 *
VK28 (20 μM)
26.6 ± 7.7†
VK28 (100 μM)
40.2 ± 7.5†